A practical approach to the laboratory diagnosis of dyslipidemia

American Journal of Clinical Pathology

Volumn 106, Issue 1, 1996, Pages 128-138

  Jialal, Ishwarlal ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Atherosclerosis; Dyslipidemia; High density lipoprotein cholesterol; Low density lipoprotein cholesterol

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; DIAGNOSTIC APPROACH ROUTE; DIFFERENTIAL DIAGNOSIS; DYSLIPIDEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LABORATORY TEST; PRIORITY JOURNAL; REVIEW;

EID: 0029891919     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.1.128     Document Type: Review

References (33)

1. Thompson GR. A Handbook of Hyperlipidemia. ed 2. London: Current Science, 1994.
2. Malloy MJ, Kane KP. Medical management of hyperlipidemic states. Adv Intern Med 1994;39:603-631.
3. Jialal I. Diagnostic Tests in Endocrinology and Diabetes: Dyslipidaemias and their investigation. London: Chapman and Hall Medical, 1994, pp 215-227.
4. Patsch W, Patsch JR, Gotto AM. The hyperlipoproteinemias. Med Clin North Am 1989:73:859-893.
5. Expert Panel. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993;269:3015-3023.
6. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992;1:445-466.
7. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease:Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
8. Shepherd J, Stuart M, Cobbe MD, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
9. National Cholesterol Education Program Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992;89:(Suppl):525-584.
10. Castelli WP, Garrison RJ, Wilson PWF, et al. Incidents of coronary heart disease and lipoprotein cholesterol levels. The Framingham Heart Study.JAMA 1986;256:2835-2838.
11. Gordon DJ, Rifkind BM. High density lipoproteins: The clinical implications of recent studies. N Engl J Med 1989;321:1311-1316.
12. Garber AM, Levins AL. Triglyceride concentration and coronary heart disease. BMJ 1994;309:2-3.
13. Chait A, Brunzell JD. The chylomicronemia syndrome. Adv Int Med 1991;31:249-273.
14. Sniderman A, Shapiro S, Marpole D, et al. Association of coronary atherosclerosis with hyperapo-beta lipoproteinemia. Proc Natl Acad Sci USA 1990;77:604-608.
15. Reaven GM. Role of insulin resistance in human disease (syndrome X): An expanded definition. Annu Rev Med 1993;44: 121-131.
16. Rahl SC Jr, Mahley RW. The role of apoprotein E genetic variants in lipoprotein disorders. J Intern Med 1992;231:653-659.
17. Smith SJ, Cooper GR, Myers GL, Sampson EJ. Biological variability in concentrations of serum lipids: Sources of variation among results from published studies and composite predicted values. Clin Chem 1993;39:1012-1022.
18. Bhatnager E, Durrington PN. Does measurement of apolipoproteins add to the clinical diagnosis and management of dyslipidemias? Curr Opin Lipidol 1993;4:299-304.
19. Cooper GR, Omar Henderson L, Smith JS, Hannon WH. Clinical applications and standardization of apoprotein measurements in the diagnostic workup of lipid disorders. Clin Chem 1991;37: 619-620.
20. Marcovina SM, Albers JJ, Henderson LO, Hannon WH. International Federation of Clinical Chemistry Study on the Standardization of Apolipoprotein A-1 and Apolipoprotein B. Curr Opin Lipidol 1991;2:355-361.
21. Rader DJ, Brewer B. Lipoprotein(a): Clinical approach to a unique atherogenic lipoprotein. JAMA 1992;267:1109-1112.
22. Barnathan ES. Has lipoprotein "little" (a) shrunk? JAMA 1993;270:2224-2225.
23. Albers JJ, Marcovina SM. Lipoprotein a quantification: Comparison of methods and strategies for standardization. Curr Opin Lipidol 1994;5:417-421.
24. Scanu AM, Lawn RM, Berg K, Dahlen GH. Lipoprotein(a) and atherosclerosis. Ann Intern Med 1991;115:209-218.
25. Siest G, Pillot T, Bailly A, et al. Apoprotein E: An important gene and protein to follow in laboratory medicine. Clin Chem 1995;41:1068-1086.
26. Stein EA, Meyers GL. National Cholesterol Education Program Recommendations for Triglyceride Measurement:Executive Summary. Clin Chem 1995;41:1421-1426.
27. McNamara JR, Cole TG, Contois JH, et al. Immunoseparation method for measurement of low density lipoprotein cholesterol directly from serum evaluated. Clin Chem 1995;41:232-240.
28. Jialal I, Hirany SV, Devaraj S, Sherwood TA. Comparison of immunoseparation method for direct measurement of LDL cholesterol with beta-quantification (ultracentrifugation). Am J Clin Pathol 1995;104:76-81.
29. Bachorik PS, Ross JW. National Cholesterol Education Program Recommendation for the Measurement of Low Density Lipoprotein Cholesterol: Executive Summary. Clin Chem 1995;41: 1414-1420.
30. Warnick RG, Wood PD. National Cholesterol Education Program Recommendations for Measurement of High Density Lipoprotein Cholesterol:Executive Summary. Clin Chem 1995;41: 1427-1433.
31. Krauss RM. Heterogeneity of plasma low density lipoproteins and atherosclerosis risk. Curr Opin Lipidol 1994;5:339-349.
32. Fruchart JC, Ailhau DG. Apoprotein A containing lipoprotein particles: Physiological role, quantification and clinical significance. Clin Chem 1992;38:793-797.
33. Jialal I, Devaraj S. Low density lipoprotein oxidation, antioxidants and atherosclerosis: A clinical biochemistry perspective. Clin Chem 1996;42:498-506.